Scarica l'app Stockscreener
44.39
4.10%
-1.90
Dopo l'orario di chiusura:
45.44
1.05
+2.37%
Precedente Chiudi:
$46.29
Aprire:
$46.29
Volume 24 ore:
2.80M
Relative Volume:
1.36
Capitalizzazione di mercato:
$2.80B
Reddito:
$18.09M
Utile/perdita netta:
$-208.87M
Rapporto P/E:
-12.64
EPS:
-3.5125
Flusso di cassa netto:
$-178.15M
1 W Prestazione:
+59.28%
1M Prestazione:
+83.51%
6M Prestazione:
+77.70%
1 anno Prestazione:
+212.39%
Intervallo 1D:
$43.84
$48.06
Intervallo di 1 settimana:
$26.65
$50.08
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
44.39 | 2.92B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
uniQure commences $150 million public offering of shares By Investing.com - Investing.com Canada
uniQure starts $150M share sale, with $22.5M extra option - Stock Titan
uniQure Announces $150 Million Proposed Public Offering - Yahoo Finance Australia
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Benzinga
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene TherapyRegenxbio (NASDAQ:RGNX) - Benzinga
uniQure Reports Promising Preliminary Results for AMT-260 Gene Therapy in Refractory Mesial Temporal Lobe Epilepsy Phase I/IIa Trial 1 – Minichart - Minichart
uniQure (QURE) CEO sells 206,100 shares and exercises stock options - Stock Titan
Uniqure N.v. Insider Sold Shares Worth $526,485, According to a Recent SEC Filing - Moomoo
uniQure (QURE) director exercises 11,685 options, sells shares under 10b5-1 - Stock Titan
uniQure (QURE) director Jack Kaye sells shares after exercising stock options - Stock Titan
Form 8K uniQure N.V. For: 22 June By Investing.com - Investing.com South Africa
uniQure (QURE) Secures FDA Reversal for Huntington's Disease Gen - GuruFocus
uniQure reports preliminary AMT-260 Phase I/IIa low-dose results; 3 of 6 patients show 79–100% seizure reduction - TradingView
uniQure (QURE) shows mixed but promising early AMT-260 MTLE results - Stock Titan
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Technical Reactions to QURE Trends in Macro Strategies - Stock Traders Daily
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval - Yahoo Finance
uniQure reports mixed results from epilepsy gene therapy trial By Investing.com - Investing.com Canada
UniQure surges on plans to seek US nod for gene therapy - MSN
uniQure reports mixed results from epilepsy gene therapy trial - Investing.com UK
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now - InvestorPlace
uniQure’s epilepsy gene therapy showed seizure drops in 3 patients - Stock Titan
uniQure (QURE) Unveils Early Data on Gene Therapy for Epilepsy - GuruFocus
What Caused uniQure's Dramatic Stock Plunge - Kavout
uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy - Benzinga
QURE Maintained by Goldman Sachs -- Price Target Raised to $46 - GuruFocus
QURE Maintained by Leerink Partners -- Price Target Raised to $7 - GuruFocus
uniQure N.V. (NASDAQ: QURE) insider sells 164,429 shares across June filings - Stock Titan
QURE Upgraded by Barclays -- Price Target Raised to $65 - GuruFocus
Uniqure NV (QURE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting - Barchart.com
QURE Maintained by RBC Capital -- Price Target Raised to $65.00 - GuruFocus
UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says - marketscreener.com
uniQure receives FDA pathway for Huntington’s disease therapy - Investing.com UK
Worldwide Healthcare Trust PLCPortfolio Holding uniQure N.V. Announces Filing Plans with U.S. Food & Drug Administration - Sharecast.com
uniQure (QURE) Receives Upgrade from Barclays with Increased Pri - GuruFocus
uniQure receives FDA pathway for Huntington’s disease therapy By Investing.com - Investing.com Australia
UniQure: AMT-130's FDA Path Reaffirms My Bull Case (NASDAQ:QURE) - Seeking Alpha
Barclays upgrades uniQure stock rating on Huntington’s timeline By Investing.com - Investing.com Australia
Barclays upgrades uniQure stock rating on Huntington’s timeline - Investing.com
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $46 to $70 - 富途牛牛
uniQure stock rating reiterated at Buy by H.C. Wainwright on FDA update - Investing.com
Leerink raises uniQure stock price target to $70 on FDA reversal By Investing.com - Investing.com South Africa
Leerink raises uniQure stock price target to $70 on FDA reversal - Investing.com
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RBC Raises Price Target on uniQure to $65 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
uniQure shares steady after FDA momentum, Huntington’s filing on radar - TechStock²
uniQure shares leap as FDA opens door to gene therapy filing - The Pharma Letter
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):